Citi reiterates Buy rating on Caribou Biosciences stock ahead of key data

Caribou Biosciences (NASDAQ:CRBU) is strategically narrowing its focus to two lead oncology programs, CB-010 and CB-011, extending its cash runway into the second half of 2027 following a 32% workforce reduction. This reprioritization precedes key clinical data readouts anticipated in late 2025, which Citi expects to generate significant enterprise value, reiterating a $6.00 price target. While H.C. Wainwright adjusted its price target to $3.00 due to the pipeline shift, both firms maintain Buy ratings, underscoring the company's compelling allogeneic CAR-T platform and solid financial position to fund its focused clinical development.

Analysis

Caribou Biosciences (CRBU) is executing a strategic pivot to concentrate resources on its two lead allogeneic CAR-T programs, CB-010 for B-cell non-Hodgkin lymphoma and CB-011 for multiple myeloma. This reprioritization involved a 32% workforce reduction and has successfully extended the company's cash runway into the second half of 2027, supported by a strong balance sheet with a 7.6x current ratio and $212.5 million in funds as of Q1 2025. The primary value inflection point for the stock is the upcoming clinical data readouts for these programs, anticipated in the second half of 2025. Analyst sentiment is positive but shows divergence on valuation; Citi reiterated its Buy rating and $6.00 price target, adding a 90-day upside view based on the platform's potential, while H.C. Wainwright also maintains a Buy but reduced its price target from $9.00 to $3.00 following the pipeline consolidation. The stock's recent 12% weekly gain and its regaining of Nasdaq minimum bid compliance signal renewed market interest ahead of these critical catalysts.

Key Decisions for Investors

• Investors should view a position in CRBU as a concentrated, high-risk/high-reward play on the binary outcome of the H2 2025 clinical data for its two lead assets, CB-010 and CB-011.
• The company's extended cash runway through H2 2027 and strong liquidity significantly mitigate near-term financing risk, providing a stable operational runway leading up to the pivotal data release.
• Note the considerable divergence between analyst price targets ($6.00 vs. $3.00) as a reflection of valuation uncertainty for the newly focused pipeline, suggesting that while upside potential exists, it is directly tied to clinical success.